

TERCICA INC  
Form DFAN14A  
June 06, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**SCHEDULE 14A**

**Proxy Statement Pursuant to Section 14(a)**

**of the Securities Exchange Act of 1934**

**(Amendment No. \_\_\_\_\_)**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

**Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

**TERCICA, INC.**

(Name of Registrant as Specified in its Charter)

**IPSEN, S.A.**

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

---

(2) Aggregate number of securities to which transaction applies:

---

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

---

(4) Proposed maximum aggregate value of transaction:

---

(5) Total fee paid:

---

Edgar Filing: TERCICA INC - Form DFAN14A

- .. Fee paid previously with preliminary materials.
  
- .. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

---

(2) Form, Schedule or Registration Statement No.:

---

(3) Filing Party:

---

(4) Date Filed:

---

Press release

**Ipsen builds a fully fledged presence in North America, significantly enhancing its geographic footprint, global specialty portfolio and growth profile**

**Endocrinology: agreement to take control of US-partner Tercica Inc.**

**Neurology: acquisition of the U.S. subsidiary of Vernalis plc, and of the North American rights for Apokyn®**

**Hematology: acquisition of all OBI-1 assets from Octagen**

**Revised financial outlook**

**Paris (France), 5 June 2008** - Ipsen (Euronext: FR0010259150; IPN) announced today that it has taken significant steps forward in building a fully fledged commercial presence in North America. In line with its strategy to globalize its specialist care business, the three transactions announced today will allow Ipsen, upon completion, to directly market its key specialist care products in the world's largest pharmaceutical market, with three global products in its portfolio (Somatuline® Autogel® / Depot, Increlex®, and, upon FDA approval, Dysport®).

In the field of endocrinology, Ipsen entered into a definitive merger agreement by which it would acquire all of the publicly held shares of Tercica Inc. the Group does not currently own at a price of \$9.0 per share in cash. This transaction, which is subject to approval by a majority of outstanding Tercica shares, has been unanimously approved by Tercica's Board of Directors following recommendation and approval by an independent special committee of the Tercica board of directors comprised of three non-management independent directors (the Special Committee).

In the field of neuromuscular disorders, the Group signed an agreement with Vernalis Ltd to acquire its US operations, Ipsen's future platform for the launch of Dysport®, and the rights to market Apokyn®, a treatment for off-episodes in moderate to severe Parkinson's Disease.

In the field of hematology, Ipsen entered into a purchase agreement with Octagen to acquire all its OBI-1 related assets in order to fully control its future development and, given the promising nature of the compound, extract more value from its direct commercialization.

Overall, through these transactions, Ipsen builds a fully fledged presence in North America, significantly enhances its geographic footprint, globalizes its specialty portfolio in endocrinology and neurology and accelerates its growth profile, notably by gaining access to new Research and Development projects.

**Jean-Luc Bélingard**, Chairman and Chief Executive Officer of Ipsen said: *These proposed transactions represent another very significant step in the strategy to globalize our fast growing specialist care franchise, both from a commercial and R&D perspective. With a fully fledged commercial infrastructure in North America, Ipsen will further enhance its growth profile, be able to seize the opportunities to expand in the world's largest pharmaceutical market and leverage its existing rich research and development pipeline. Furthermore, upon closing of the transactions, Ipsen will notably add new promising R&D projects, with the full rights to OBI-1, the recombinant hGH and IGF-1 combination therapy or the expansion of Somatuline® into neuroendocrine tumors in North America.* Jean-Luc Bélingard added: *We strongly believe that these landmark transactions represent a cost-effective way to enter the North American market by creating a US platform with the potential to generate sales in excess of \$300 million in 2012 and close to \$1 billion by the end of the next decade.*

## 1. Endocrinology: agreement to take control of US-partner Tercica Inc.

A subsidiary of Ipsen has entered into a definitive merger agreement by which it will acquire the remaining approximately 44.9 million fully diluted shares of Tercica (NASDAQ: TRCA) not owned by the Ipsen group for \$9.0 per share in cash, for a total purchase price of approximately \$404 million. Ipsen and its subsidiaries currently own approximately 25.3% of the outstanding shares of the U.S. biopharmaceutical company focused on endocrinology. In connection with the agreement, Ipsen has also committed to exercise its warrants to purchase Tercica common stock for a total exercise price of \$37 million and to convert all of its outstanding convertible notes into Tercica common stock; following such exercise and conversion, Ipsen and its subsidiaries will then own approximately 42.7% of Tercica's common stock assuming no further exercise of stock options. Ipsen intends to finance this transaction through a combination of existing internal financial resources and bank loan financing already in place.

The proposed cash offer represents, with full certainty to Tercica Inc.'s shareholders, a 104% premium to Tercica's closing price on June 4, 2008 and a premium of 74% and 49% to the volume-weighted average closing share price during the last three months and six months respectively.

Tercica's Board of Directors, following the unanimous recommendation and approval of Tercica's Special Committee, who was advised by independent legal and financial advisors, has approved the merger agreement and recommended that Tercica stockholders vote to approve the merger.

Ipsen has negotiated an arms-length agreement with the Tercica Special Committee that will be subject to the affirmative vote of the holders of a majority of the Tercica shares outstanding on the record date as well as customary regulatory approvals.

The exact timing of completion of the merger is dependent upon the review and clearance of the proxy statement and other necessary filings with the U.S. Securities and Exchange Commission. Further details about the proxy statement are set forth at the end of this press release.

*The combination of Ipsen's and Tercica's development portfolios provides the opportunity to create a global leading endocrinology company* said **John A. Scarlett**, M.D., Chief Executive Officer of Tercica Inc. *We believe this transaction recognizes the value we have created at Tercica, and provides our stockholders with attractive financial terms.*

## 2. Neurology: acquisition of the U.S. subsidiary of Vernalis plc, and of the North American rights for Apokyn®

Ipsen today announced that it has reached an agreement with UK-based Vernalis (R&D) Limited and Vernalis plc (LSE: VER) to acquire its US subsidiary Vernalis Pharmaceuticals, Inc. (Vernalis Inc.), and the rights to develop and market Apokyn<sup>®</sup> in the US, for a total consideration of up to \$12.5 million (or \$8.1 million<sup>1</sup>). This transaction brings Ipsen an established and highly experienced neurology commercial team, who already market Apokyn<sup>®</sup> (apomorphine HCl) in the US to neurology specialty physicians, many of which are potential prescribers for Dysport<sup>®</sup>. In addition, Ipsen will subscribe to the equivalent of \$5.0 million (or \$3.2 million) of newly issued shares of Vernalis plc, and both companies will join forces to develop specific Ipsen neurology R&D programs. This transaction is subject to Vernalis plc's shareholders meeting approval.

The Food and Drug Administration (FDA) accepted for filing Dysport<sup>®</sup> (botulinum toxin of type A) for cervical dystonia with in January 2008. In this context, this transaction gives Ipsen in a timely manner the US commercial and managed care expertise as well as the infrastructure platform from which to market Dysport<sup>®</sup> once the FDA has granted market approval. The acquisition of Vernalis Inc. is therefore strategically important for Ipsen, representing a significant step forward in building a global specialist care business with a direct presence in neurology in North America, the world's largest pharmaceutical market, and in further globalizing its specialist care business.

<sup>1</sup> Using a 1.55 \$/€ exchange rate

Ipsen has agreed with Vernalis plc to acquire all the shares of its US subsidiary Vernalis Inc, and to acquire from its UK subsidiary Vernalis (R&D) Limited the rights and assets required to develop and market Apokyn® in the US, for a total consideration of up to \$12.5 million (or 8.1 million).

In this context, Ipsen will pay \$6.5 million to Vernalis plc (or 4.2 million) in upfront payments and additional payments of up to \$5.0 million (or 3.2 million) contingent on certain commercial and operating milestones. In order to demonstrate its commitment to the business, Ipsen will also underwrite before closing \$2.2 million (or 1.4 million) of specific corporate and commercial expenses of Vernalis Inc.

Upon approval by Vernalis plc's shareholders, Ipsen will also subscribe to 35,253,134 newly issued ordinary shares of Vernalis plc at 7.26 pence per share, representing a 20% premium over the 3-day average closing ordinary share price of Vernalis plc prior to the announcement of the acquisition on the London Stock Exchange.

Ipsen and Vernalis plc have also agreed to negotiate a joint venture to raise funding for the development of a selection of Ipsen's neurology pipeline projects. If this does not proceed, Ipsen will make a payment of \$1.0 million to Vernalis.

**John Slater**, Chief Operating Officer of Vernalis plc, said: *The fact that Ipsen selected Vernalis Pharmaceuticals Inc. as the basis for its North American commercial presence in neurology is a strong recognition that the team has set up a high-profile, professional presence in this field, initially around its Parkinson's disease product, Apokyn®. I am both proud and pleased that they can bring so much to Ipsen whilst embracing new and exciting challenges including the forthcoming launch of Dysport® in the US.*

### **3. Hematology: acquisition of all OBI-1 related assets from Octagen**

Ipsen and Octagen today announced that they have entered into an Asset Purchase Agreement pursuant to which Ipsen will, upon closing, acquire all of Octagen's assets related to OBI-1 and get full control over OBI-1's clinical development.

Emory University (Atlanta, GA, USA) licensed its OBI-1 patents to Octagen (Wilmington, Delaware, USA), who in turn granted a worldwide, exclusive sublicense to Ipsen in 1998. OBI-1 is a biotech drug being developed to treat haemophilia and fully produced by Ipsen at its recombinant manufacturing sites located in Milford (Massachusetts, USA) and Wrexham (Wales, UK). Prior to the transaction, Octagen was responsible for the pre-clinical and clinical development of OBI-1 and sublicensed certain rights to Ipsen in connection with the manufacturing, regulatory activities and commercialization of OBI-1. In that context, Ipsen had agreed to make certain milestone payments to Octagen and to pay royalties based on OBI-1 future net sales. At the same time, Ipsen had purchased 21.45% of Octagen's share capital.

Pursuant to the Asset Purchase Agreement announced today, upon closing, Ipsen will make an upfront payment of \$10.5 million ( 6.8 million) to Octagen. Also Ipsen will make future additional milestone payments contingent on the product being allowed into Phase III, and later on receipt of marketing approvals in the U.S. and Europe, potentially totaling up to \$26.0 million ( 16.8 million). In addition, Ipsen shall pay, once the product is marketed and for a defined duration, a low to mid single digit royalty on its net sales in each country, on an upward sliding scale depending on certain sales thresholds.

Immediately following the completion of the acquisition of all of the assets related to OBI-1, Ipsen will also redeem its stake in Octagen.

### Revised financial outlook

Ipsen confirms its standalone **full year 2008** objectives, as announced on February 27, 2008. However, once the closing dates of the transactions announced today are known, the Group will revise these objectives, to reflect the impact of the full consolidation of the newly acquired entities.

For the **full year 2009**, based on currently available information and assuming all transactions are closed, the Group has set for itself the following objectives:

A total net sales growth of 12.0 to 14.0% compared to Ipsen's standalone objectives for 2008, at constant exchange rate

An operating margin of around 15.0% of sales, notably taking into account the pre-launch costs of Dysport® in North America and excluding any transaction-related recordings or purchase accounting impacts;

A continued Research and Development expense of 19.0 to 21.0% of total net sales.

Following these transactions, the Group expects to return to its 2007 operating margin level in 2011 excluding any assumption on potential future GLP-1 royalty stream.

Through the transactions announced today, Ipsen expects to create a North American platform able to generate sales in excess of \$300 million in 2012, growing double-digit worldwide, and potentially able to reach \$1 billion by the end of the next decade.

### Ipsen - Analyst and Investor conference call and webcast (in English)

An investor presentation is available on Ipsen's Investor Relations website [www.ipsen.com](http://www.ipsen.com). Ipsen will host a conference call on 5 June 2008 at 1.00 p.m. (Paris time). A live webcast will be available at [www.ipsen.com](http://www.ipsen.com). The webcast will be archived on the Ipsen website for 3 months following the live call. Callers should dial in approximately 5 to 10 minutes prior to the start of the call. No reservation is necessary to participate in the call. The telephone numbers to join the conference call are, from France and Europe: +33 (0) 1 70 99 43 04 and from the United States: +1 718 354 1391. No access code is necessary.

A replay will be available soon after the live call. The telephone numbers to access the replay are, from France and Europe: +33 (0) 1 71 23 02 48 and from the United States: +1 718 354 1112. The access code is 1692745#. The replay will be available for one week following the live call.

### Important additional information and where to find it

In connection with the merger, Tercica will file a proxy statement with the Securities and Exchange Commission and in due course will mail the proxy statement to Tercica stockholders in connection with a meeting of Tercica stockholders to seek approval for the merger. The exact timing of completion of the merger is dependent on the review and clearance of the proxy statement, and other necessary filings, with the Securities and Exchange Commission. Tercica stockholders are urged to read the proxy statement in full when it becomes available because it will contain important information. Copies of the proxy statement, as well as other filings containing information about Ipsen, its subsidiaries and Tercica, will be made available in due course, without charge, at the internet site of the Securities and Exchange Commission ([www.sec.gov](http://www.sec.gov)). The proxy statement and such other documents may also be obtained for free from the [Investor Relations] section of the Tercica's internet site ([www.tercica.com](http://www.tercica.com)) or by directing a request to Tercica at: 2000 Sierra Point Parkway, Suite 400, Brisbane, CA 94005, Attention: Stephen Rosenfield

### Participants in the Solicitation

Tercica, Ipsen and their respective directors, executive officers, affiliates and other person may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Ipsen's directors and executive officers is available in Ipsen's Registration Document filed with the Autorité des Marchés Financiers and available on its website [www.ipsen.com](http://www.ipsen.com). Information regarding Tercica's directors and executive officers is available in Tercica's Form 10-K for the year ended December 31, 2007 which was filed with the Securities and Exchange Commission on





February 29, 2008. Information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement, the Schedule 13E-3 transaction statement and other relevant materials to be filed with the Securities and Exchange Commission when they become available. This press release and the related Agreement and Plan of Merger will be filed with the Securities and Exchange Commission pursuant to the requirements of U.S. securities laws.

### **About Ipsen**

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2007, Research and Development expenditure was about 185 million, in excess of 20% of consolidated sales, which amounted to 920.5 million while total revenues amounted to 993.8 million. Ipsen's shares are traded on Segment A of Euronext by EuronextTM (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the Service de Règlement Différé (SRD) and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at [www.ipсен.com](http://www.ipсен.com).

### **Ipsen Forward-looking statements**

The forward-looking statements and targets contained herein are based on Ipsen's management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. The Group does not commit nor gives any guarantee that it will meet the targets mentioned above. Moreover, the Research and Development process involves several stages at each of which there is a substantial risk that the Group will fail to achieve its objectives and be forced to abandon its efforts in respect of a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group also faces the risk of product liability claims relating to their safety, notably for its neuromuscular disorders products (marketed under the brand name Dysport® notably) that may cause, or may appear to cause, serious adverse side effects or potentially dangerous drug interactions if misused or improperly prescribed. The Group is subject to adverse event reporting pharmacovigilance obligations that require to report to regulatory authorities if the Group's products are associated with serious adverse events, including patient death or serious injury. These adverse events, among others, could result in additional regulatory constraints, such as additional requests from the regulatory authorities during reviews of applications filed for marketing approvals in various countries which could delay the launch time of the given products in new markets, the performance of costly post-approval clinical studies or revisions to the approved labeling limiting the indications or patient population for the Group's products or could even lead to the withdrawal of a product from the market. Such events could harm the sales of the product and therefore have a material negative impact on the Group's financial situation. Furthermore, any adverse publicity associated with such an event could cause consumers to seek alternatives to the Group's products, which may cause sales to decline, even if the Ipsen product at stake is ultimately determined not to have been the cause of the reported serious adverse event. Ipsen's business is subject to the risk factors outlined in its information documents filed with the French *Autorité des Marchés Financiers*.

For further information:

**Ipsen**

**Didier Véron**

Director of Public Affairs and Corporate Communications

Tel.: +33 (0)1 44 30 42 38

Fax: +33 (0)1 44 30 42 04

E-mail: [didier.veron@ipsen.com](mailto:didier.veron@ipsen.com)

**David Schilansky**

Investor Relations Officer

Tel.: +33 (0)1 44 30 43 31

Fax: +33 (0)1 44 30 43 21

E-mail: [david.schilansky@ipsen.com](mailto:david.schilansky@ipsen.com)

**Brunswick Group (press contacts)**

Robin Gilliland

Telephone: +1- 212 333 3810

Email: [rgilliland@brunswickgroup.com](mailto:rgilliland@brunswickgroup.com)

Justine McIlroy

Telephone + 44 (0)207 396 3536

Fax + 44 (0) 207 936 7836

Email: [jmcilroy@brunswickgroup.com](mailto:jmcilroy@brunswickgroup.com)

## APPENDICES

### About Apokyn®

Apokyn® (apomorphine hydrochloride injection) is the only therapy available in the US for the treatment of "off" episodes (re-emergence of Parkinson's disease symptoms) associated with advanced Parkinson's disease. It is used as an adjunct to other Parkinson's disease medications and is administered, as needed, by means of an injector pen to treat periods of poor mobility in people with advanced disease. In April 2004, Apokyn® received FDA approval with Orphan Drug designation to treat advanced Parkinson's disease patients in the U.S. who experience the severe on/off motor fluctuations that are unresponsive to other oral Parkinson's disease therapies. Approximately 112,000 (source: Vernalis) patients with Parkinson's disease experience such "off" episodes despite optimal oral Parkinson's disease therapy. In clinical studies, Apokyn® has been shown to be effective in the acute, intermittent treatment of "off" episodes demonstrating a highly significant improvement in Unified Parkinson's Disease Rating Scale (UPDRS) Part III motor scores at 20 minutes, with statistical improvements in some measures noted as early as 10 minutes (the UPDRS is used by researchers and clinicians around the world to measure disease severity in patients).

It is estimated that approximately 1.5 million people in the U.S. (source: Vernalis) have Parkinson's disease, a condition that results from selective degeneration of an area of the brain called the substantia nigra, which is located towards the base of the brain in the basal ganglia. Normally these nerve cells release dopamine—a chemical that transmits signals between nerve cells (called a neurotransmitter). This central signalling pathway is essential for the fine control of movement and posture, and breakdown results in the symptoms of Parkinson's disease, namely tremor, rigidity, slow movements and postural instability. Muscle rigidity can become so severe as to result in "freezing"—also referred to as "off" episodes, when patients are rendered immobile. Patients also suffer from problems relating to impaired control of blood pressure (postural hypotension) and gut motility, which can impair the absorption of food and drugs. The disease is progressive and the signs and symptoms generally worsen over time. However, while Parkinson's disease may eventually be disabling, the disease often progresses gradually and with appropriate treatment many patients have a number of years of productive life after initial diagnosis.

### About Dysport®

The active substance in Dysport® is a botulinum neurotoxin type A complex, which acts at the level of the neuromuscular junction in the targeted muscle. Dysport®, Ipsen's botulinum toxin type A, is a neuromuscular blocking toxin which acts to block acetylcholine release at motor nerve ends and reduces muscular spasm. It was initially developed for the treatment of movement disorders such as cervical dystonia (a chronic condition in which the neck is twisted or deviated), blepharospasm (involuntary eye closure), hemifacial spasm and various forms of muscle spasticity, including post-stroke arm spasticity, spasticity of the lower limbs (calf) in adults and children with cerebral palsy. Dysport® was originally launched in the United Kingdom in 1991 and has marketing authorisations in over 70 countries.

The product is currently referred to as Reloxin® in the United States aesthetic market and Dysport® for medical and aesthetic markets.

### About Vernalis plc

Vernalis is a specialty bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova® and Apokyn®, and a development pipeline focused on neurology and central nervous system disorders. The company has six products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec, Endo, Menarini and Chiesi.

### About Vernalis Inc.

Vernalis Inc. is the North American commercial affiliate of Vernalis plc. Vernalis Inc. is a fully functional commercial operation operating in the field of neurology. The company markets Apokyn® (apomorphine HCl) in North America. Vernalis Inc. is composed of 55 staff, with considerable industry experience, a strong track record in neurology and an established and strong relationship with Managed Care organisations.

### **About Octagen**

Founded in November 1997, Octagen Corporation (Octagen) is a privately held biopharmaceutical company whose mission is to develop and commercialize improved therapies for hemophilia and other genetic disorders. Octagen's most advanced project, now in Phase II clinical trials, involves the development of recombinant porcine Factor VIII (rpfVIII) and is developed in collaboration with Ipsen. Octagen's website is [www.octagen.com](http://www.octagen.com).

### **About hemophilia A**

Congenital hemophilia A is a genetic bleeding disorder resulting in a deficiency of coagulation FVIII. This disease affects males predominantly with an incidence of 1 in 5000 male births. According to the Centers for Disease Control there are approximately 13000 people living with hemophilia A in the US. Hemophilia A is characterized by frequent spontaneous bleeding episode as well as prolonged bleeding from trauma or surgery. Treatment and prevention of bleeding episodes consist in replacing the missing factor FVIII with recombinant or plasma derived human FVIII.

A major complication in the treatment of hemophilia A patients is the development of antibodies (called inhibitors) to human FVIII. Approximately 30% of hemophilia A patients will develop antibodies to human FVIII in their life time. For those patients control of bleeding episodes relies on treatment that bypasses the need for FVIII.

The development of antibodies to human FVIII can also occur in individuals with normal coagulation. These auto-antibodies neutralize circulating FVIII making it no longer available, thus creating a deficiency in FVIII. Those individuals are diagnosed with acquired hemophilia A.

Acquired hemophilia A is a rare disease affecting about 1.48 individuals per million with an estimated 445 cases per year in the US. Acquired hemophilia A is often associated with auto-immune disease, malignancy or pregnancy, although in about 50% of the cases there is no underlying disease. Clinical manifestation of acquired hemophilia includes spontaneous bleeding or prolonged bleeding due to minimal trauma or surgery and is more severe and anatomically diverse than in congenital hemophilia A.

Replacement therapy with human FVIII is of limited benefit because it is rapidly neutralized by circulating antibodies. For those patients control of bleeding episodes also relies on treatment that bypasses the need for FVIII.

### **About OBI-1**

OBI-1 is a recombinant porcine Factor VIII. Since porcine FVIII (pFVIII) possesses low cross reactivity to anti-hFVIII antibodies, it is expected that OBI-1 can be used to stop bleeding in hemophilia patients with inhibitor using the same natural pathway as human Factor VIII for non inhibitor patients.

Phase I and II clinical trials have been conducted with OBI-1 in the United States, Canada, South Africa and Russia. Promising results of a phase II study on OBI-1 were presented to the American Society of Hematology in December 2007 stating that OBI-1 can be given as a short infusion. It was effective in controlling all bleeds which occurred in this study and was well tolerated.<sup>1</sup> Additional studies are now planned to optimize dose range for OBI-1 and to confirm the long term safety and efficacy of OBI-1 in the treatment of bleeds in a larger cohort of individuals with congenital hemophilia A complicated by the presence of hFVIII inhibitors, and with acquired hemophilia A.

### **About Tercica**

Tercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for short stature and other metabolic disorders. For further information on Tercica, please visit [www.tercica.com](http://www.tercica.com).

<sup>1</sup> A Phase II Open-Label Study Evaluating Hemostatic Activity, Pharmacokinetics and Safety of Recombinant Porcine Factor VIII (rpFVIII, OBI-1) in Hemophilia A Patients with Inhibitors Directed Against Human FVIII (hFVIII), Johnny Mahlangu et al., American Society of Hematology, December 2007



Ipsen builds a fully fledged presence in  
North America significantly enhancing its  
geographic footprint, global specialty  
portfolio and growth profile  
5 June 2008

Disclaimer  
This  
presentation  
includes  
only  
summary  
information  
and

does  
not  
purport  
to  
be  
comprehensive.  
Forward-looking  
statements,  
targets  
and  
estimates  
contained  
herein  
are  
for  
illustrative  
purposes  
only  
and  
are  
based  
on  
management's  
current  
views  
and  
assumptions.  
Such  
statements  
involve  
known  
and  
unknown  
risks  
and  
uncertainties  
that  
may  
cause  
actual  
results,  
performance  
or  
events  
to  
differ  
materially  
from  
those  
anticipated



in  
the  
summary  
information.  
The  
Company  
expressly  
disclaims  
any  
obligation  
or  
undertaking  
to  
update  
or  
revise  
any  
forward-looking  
statements,  
targets  
or  
estimates  
contained  
in  
this  
presentation  
to  
reflect  
any  
change  
in  
events,  
conditions,  
assumptions  
or  
circumstances  
on  
which  
any  
such  
statements  
are  
based  
unless  
so  
required  
by  
applicable  
law.  
All

product  
names  
listed  
in  
this  
document  
are  
either  
licensed  
to  
the  
Ipsen  
Group  
or  
are  
registered  
trademarks  
of  
the  
Ipsen  
Group  
or  
its  
partners  
2

Other important information  
Important additional information and where to find it  
In  
connection  
with  
the  
merger,  
Tercica

will  
file  
a  
proxy  
statement  
with  
the  
Securities  
and  
Exchange  
Commission  
and  
in  
due  
course  
will  
mail  
the  
proxy  
statement  
to  
Tercica  
stockholders  
in  
connection  
with  
a  
meeting  
of  
Tercica  
stockholders  
to  
seek  
approval  
for  
the  
merger.  
The  
exact  
timing  
of  
completion  
of  
the  
merger  
is  
dependent  
on  
the  
review

and  
clearance  
of  
the  
proxy  
statement,  
and  
other  
necessary  
filings,  
with  
the  
Securities  
and  
Exchange  
Commission.  
Tercica  
stockholders  
are  
urged  
to  
read  
the  
proxy  
statement  
in  
full  
when  
it  
becomes  
available  
because  
it  
will  
contain  
important  
information.  
Copies  
of  
the  
proxy  
statement,  
as  
well  
as  
other  
filings  
containing  
information  
about

Ipsen,  
its  
subsidiaries  
and  
Tercica,  
will  
be  
made  
available  
in  
due  
course,  
without  
charge,  
at  
the  
internet  
site  
of  
the  
Securities  
and  
Exchange  
Commission  
([www.sec.gov](http://www.sec.gov)).  
The  
proxy  
statement  
and  
such  
other  
documents  
may  
also  
be  
obtained  
for  
free  
form  
the  
[Investor  
Relations]  
section  
of  
the  
Tercica's  
internet  
site  
([www.tercica.com](http://www.tercica.com))  
or

by  
directing  
a  
request  
to  
Tercica  
at:  
2000  
Sierra  
Point  
Parkway,  
Suite  
400,  
Brisbane,  
CA  
94005,  
Attention:  
Stephen  
Rosenfield  
Participants in the Solicitation  
Tercica,  
Ipsen  
and  
their  
respective  
directors,  
executive  
officers,  
affiliates  
and  
other  
person  
may  
be  
deemed  
to  
be  
participants  
in  
the  
solicitation  
of  
proxies  
in  
respect  
of  
the  
proposed  
transaction.  
Information

regarding  
Ipsen's  
directors  
and  
executive  
officers  
is  
available  
in  
Ipsen's  
Registration  
Document  
filed  
with  
the  
Autorité  
des  
Marchés  
Financiers  
and  
available  
on  
its  
website  
[www.ipsen.com](http://www.ipsen.com).  
Information  
regarding  
Tercica's  
directors  
and  
executive  
officers  
is  
available  
in  
Tercica's  
Form  
10-K  
for  
the  
year  
ended  
December  
31,  
2007  
which  
was  
filed  
with  
the



Securities  
and  
Exchange  
Commission  
on  
February  
29,  
2008.  
Information  
regarding  
the  
participants  
in  
the  
proxy  
solicitation  
and  
a  
description  
of  
their  
direct  
and  
indirect  
interests,  
by  
security  
holdings  
or  
otherwise,  
will  
be  
contained  
in  
the  
proxy  
statement,  
the  
Schedule  
13E-3  
transaction  
statement  
and  
other  
relevant  
materials  
to  
be  
filed  
with

the  
Securities  
and  
Exchange  
Commission  
when  
they  
become  
available.

This  
press  
release  
and  
the  
related  
Agreement

and  
Plan  
of  
Merger  
will

be  
filed  
with  
the  
Securities  
and  
Exchange  
Commission  
pursuant  
to  
the  
requirements  
of  
U.S.  
securities  
laws.

3

An innovation driven International Specialty Pharma  
Group  
Three targeted areas : Oncology, Endocrinology and Neuromuscular  
Disorders  
5 key products accounting for ~ 55% of drug sales  
Growing at a double digit rate  
A strategic focus on  
specialist care

worldwide

A primary care franchise focused on gastroenterology, cognitive disorders and cardiovascular

A focus on selected geographies including France, China and Russia

A sound business yielding recurring cashflow and contributing to R&D financing

Focused on hormone-dependent diseases, peptide and protein engineering and innovative delivery systems

R&D expense in excess of 20% of sales

4 centers

in Boston, Paris, London and Barcelona

Alliances with international industry leaders in US, Europe and Japan and best-in-class universities around the world

Ipsen's business partners include Galderma, Genentech, GTx, Medicis, Roche, and Teijin

A historic presence

in primary care

A truly

differentiating and international R&D

capability

A recognised

strategic partner

A fully-fledged peptide manufacturing capability

Two FDA-approved manufacturing facilities

An integrated player

4

Today: announcement of three landmark transactions

5

Agreement with Tercica Inc. s Special Committee and Board of Directors to purchase the remainder of Tercica Inc. s outstanding common stock

1

2

Agreement with Vernalis plc. to acquire its US operations and rights

for Apokyn

®

3

Agreement with Octagen to acquire all OBI-1 related assets

Unfolding our strategy  
3 botulinum  
toxin dossiers  
under review  
(US and Europe)  
Choice of a  
commercialisation  
option for

Dysport

®

in the US

Add a  
companion  
product to  
Dysport

®

Disclosure by  
Roche of GLP-1  
(R1583)  
phase II results  
and potential  
phase III  
initiation

Adenuric

®

(febuxostat)  
partnership  
opportunities in  
Europe  
OBI-1  
development  
optimisation  
Somatuline

®

US

sales ramp-up

Reloxin

®

filing in the US

Increlex

®

sales

ramp up in

Europe

Enrich R&D

pipeline

6

Strategic Priorities

GROW

top-line and profits in  
specialist care by providing  
innovative drug therapy

OPTIMIZE

returns of primary  
care through selected product life  
cycle management, partnerships  
and focused investments

Mission Statement



To be a worldwide best-in-class provider of innovative drugs, addressing unmet medical needs in its targeted therapeutic areas  
GLOBALIZE  
through active  
geographical expansion policy

Strategic rationale for the  
transactions

Jean-Luc Bélingard, Chairman & CEO

8

Growing and globalising our specialist care business

Clear execution of our globalisation strategy of our fast growing specialist care portfolio

1

2

4

Somatuline

®

,

Increlex

®

and

upon

FDA

approval,

Dysport

®

and

OBI-1

will

become

global

products

directly

marketed

by

Ipsen

5

leveraging on the existing focus and expertise of the acquired organizations

Vernalis

Inc.

is

an

operational

business

with

an

existing

synergistic

product

on

the

market,

Apokyn

®

,

targeting

an

overlapping

prescriber

base

with

Dysport

®

and

Tercica

already

markets  
Increlex  
®  
and  
Somatuline  
®  
in  
the  
US

and delivering significant potential future revenue opportunity, expected to exceed \$300 million in 2012 and potentially approaching \$1 billion by the end of the next decade

executed in favourable forex

market conditions

Cost-effectively

enhancing

our

growth

prospects,

enriching

our

pipeline

while

minimising execution risks of entering the US market

3

while enriching our pipeline with new significant R&D projects

Full

rights

to

OBI-1,

combination

of

GH

and

IGF-1,

expansion

of

Somatuline

in

NET

in

the

US,

expansion

of

Increlex

®

s

indication

Leading field-proven products in Europe  
Somatostatin  
analogue  
Highly differentiated product  
Main indications: acromegaly/NET  
Marketed in Europe since 1995  
Approved in the US in August 07  
Somatuline

®

Dysport

®

Botulinum Toxin of Type A

Efficient and field proven product

Main indication: dystonia, spasticity \*

Marketed in Europe since 1991

Under review by FDA since Jan.08

9

n°1 or n°2 in most markets where Ipsen operates

.now entering North America, the largest pharmaceutical market in the world

\*cervical

dystonia,

cerebral

palsy

in

children,

muscle

spasticity,

blepharospasm/hemifacial

spasm

US entry

through

Proposed acquisition of

Tercica Inc.

Proposed acquisition of

Vernalis Inc.

10

An improved geographic mix and acceleration of specialty care

Acceleration of specialty care

(2012E indicative sales trend)

~40%

~30%

~60%

~70%



Ipsen standalone  
Ipsen combined  
Primary care  
Specialty care \*  
Improved geographic mix  
(2012E indicative sales trend)  
~25%  
~20%  
~50%  
~45%  
~15%  
~25%  
~20%  
Ipsen standalone  
Ipsen combined  
France  
Other european countries  
North America \*  
RoW  
\* using  
a 1.55 /\$ exchange rate

Establishing Ipsen a  
leading global player in  
endocrinology  
Jean-Luc Bélingard, Chairman & CEO

12  
Growing and globalising our endocrinology business  
Creation  
of  
a  
global  
endocrinology  
business

with  
Somatuline

®

and

Increlex

®

,  
two global products

1

2

3

4

leveraging the focused market reach and R&D pipeline of Tercica

with a significant revenue opportunity

Establishing Ipsen as the leading player in endocrinology, with strong growth prospects

representing another step forward to transform Ipsen into a global specialist care

company, with a strong international footprint and an enriched R&D pipeline

Cumulated revenue opportunity estimated to exceed \$250 million in 2012

13

A progressive step-up in Tercica minimizing execution risks

July

2006

Ipsen and Tercica enter  
into a strategic

partnership and cross  
licensing agreement

Somatuline

®

Depot

NDA submitted to FDA

November

2006

December

2006

Insmed

found infringing

Tercica's patents

March

2007

Litigation settlement

reached with Insmed

August

2007

Increlex

®

receives EMEA

marketing approval

Somatuline

®

receives

FDA marketing approval

December

2007

January

2008

Ipsen launches Increlex

®

in

Germany and the UK

Tercica launches

Somatuline

®

Depot in the US

Next generation GH phase II

clinical trial initiated

January

2008

Ipsen believes that it is now time to be fully responsible  
for the execution of the commercialisation of Somatuline

®

Depot in North America and

for the development of promising R&D projects

14

Selected transaction terms

Ipsen has agreed, subject to stockholder approval, to acquire all outstanding shares of Tercica Inc. that the Ipsen Group does not currently own (approximately 44.9 million shares on a fully diluted basis)

\$9.0 per share (100% cash consideration)

Tercica Inc.'s Special Committee of Independent Directors has unanimously approved the transaction and recommended it to Tercica's stockholders

A special stockholder meeting will be called by Tercica Inc. to vote on the proposed merger

Subject to stockholder approval and customary regulatory approvals and other conditions



15  
Increlex  
®  
and Somatuline  
®  
: significant market opportunities  
Increlex  
®

in severe primary IGFD

Somatuline

®

in acromegaly

Significant morbidity and mortality

1,2

North America: ~ 15,000 patients

Orphan drug status

Launched in January 2008 by Tercica

1)

Orme SM et al. JCEM 83: 2730-4, 1998.

2)

Clayton RN et al. J Endocrinol (Suppl 1): S23-9, 1997.

Severe

cases

of

short

stature

children

not

responding

to hGH

replacement therapy

North America: ~ 6,000 patients

Orphan Drug status

North America revenues of \$9.6 million in 2007

Expansion in NET

Expansion in Primary IGFD

Cumulated revenue opportunity in excess of \$250 million in 2012

A commercial platform from which to launch future compounds  
A rich Endocrinology pipeline  
Dopastatin

BIM-23A760 (Pituitary Tumors)  
Dopastatin

BIM-23A760 (Pituitary Tumors)  
Melanocortin

Program

MC4 Agonist (Obesity/Metabolic Syn)

MC4 Antagonist (Wasting Diseases)  
Melanocortin  
Program

MC4 Agonist (Obesity/Metabolic Syn)

MC4 Antagonist (Wasting Diseases)  
Ghrelin agonist

BIM-28131 (Wasting Diseases)  
Ghrelin agonist

BIM-28131 (Wasting Diseases)  
Lanreotide

Combination  
therapy  
with  
Somavert  
in  
refractory acromegaly

Treatment of asymptomatic NET  
Lanreotide

Combination  
therapy  
with  
Somavert  
in  
refractory acromegaly

Treatment of asymptomatic NET  
Increlex

Daily administration

Expanded use to primary IGFD  
A strong and unique portfolio  
IGF-1 and GH combination therapy

16  
A global care solution  
in

growth disorders worldwide  
The strength of a single global  
voice in the market

Creating a successful  
commercial infrastructure  
in neurology in the US  
Stéphane  
Thirolaix, Executive Vice President,  
Corporate Development

18

Growing and globalising our neurology business

Creation of a global neurology business with a direct presence in the US

1

2

3

4

leveraging the existing focus and expertise of the Vernalis US organization

with a significant revenue opportunity, expected to reach \$100 million at peak

Another step forward in paving the way for growth

representing another step forward to transform Ipsen into a global specialist care company, with a strong international footprint

A total revenue opportunity estimated to exceed \$50 million in 2012

Vernalis Inc. s profile  
The operations  
Established December 2005  
Headquartered in Morristown, N.J.  
54  
staff positions  
The product: Apokyn  
®



FDA approval in April 2004 with an Orphan

Drug status

Launched in July 2004, with market  
exclusivity until 2011

Fulfilling

a

high

unmet

medical

need:

only

product

indicated

for

and

effective

in

the

acute

treatment

of

off

episodes

in

patients

with

advanced

Parkinson s

disease

Vernalis Inc. s 2007 financials

Indicative sales of \$8 million

Indicative operating loss of \$(20) million

19

Apokyn

®

: a convenient and efficient product

A rapid and reliable onset of action:

Apokyn

®

provides an improvement in motor symptoms  
equal to that of levodopa

within 20 minutes of an injection as shown in the US clinical studies:

95%

of

off

episodes

were

reversed

with

Apokyn

®

when

used

as

needed

Efficacy was maintained in patients with average therapy duration of 14.5 months

Most patients responded to doses of 0.3 – 0.6 mL, average dosing frequency was 2.5 times per day

A convenient administration:

subcutaneous injection dosed with an adjustable, reusable pen

(29 gauge needle)

Used on an as needed

basis: **the patient decides when to use it allowing more control over**

the treatment, reinforced by the ability to inject at home

20

Apokyn

®

is promoted in moderate to severe PAD

to complement other therapies or when other therapies are not effective

Key transaction terms

Consideration structure

Upfront payment of \$6.5 million ( 4.2 m)

Additional payments of up to \$6.0 million \*  
( 3.9 m) depending upon certain commercial  
and operational milestones

Ipsen to underwrite, at signing, certain  
commercial and operating expenses of

Vernalis Inc. of up to \$2.2 million ( 1.4 m)

Share subscription

Ipsen to subscribe for \$5.0 m ( 3.2 m) newly issued shares in Vernalis plc.,

ie. ~9.7% of Vernalis plc. s share capital

Subscription at £7.260 pence per share, representing a 20% premium on 3 day average before announcement

Consolidation

Expected to be fully consolidated in Ipsen s accounts in H2 2008

21

\* Including \$1.0 million if a R&D JV between Ipsen and Vernalis plc on selected Ipsen neurology pipeline items does not proceed

Dysport  
®  
: a strong brand, with  
well  
established  
positions  
93  
129

113

83

69

60

2002

2003

2004

2005

2006

2007

5 main

Western

European

countries

43%

Other

Europe

25%

RoW

32%

02-07 Sales CAGR:

+17%

Used globally for therapeutic indications: cervical dystonia, cerebral

palsy

in

children,

muscle

spasticity,

blepharospasm,

hemifacial

spasm

Launched in the UK in

1991

Marketing authorisations in over 70 countries (in Europe (including

Russia), Asia and Latin America)

Equivalent market share in therapeutic use to that of its main

competitor in the 5 main European countries

Dysport

®

was filed for review by the FDA at the end of January 2008

for cervical dystonia.

22

Sales breakdown in 2007

Apokyn

®

and Dysport

®

to be promoted by the same sales force

2002 to 2005 are in French GAAP

Why Vernalis Inc. fits with Ipsen

A CNS focused company rightly sized to maximize the launch of Dysport

®

Strong managed healthcare experience, especially for injectable drugs

A relevant and targeted market reach,  
with largely similar prescriber base between Dysport

®

and Apokyn



®

Vernalis Inc. today

covers ~75% of US movement disorder specialists and neurologists

A sound commercial strategy

based on strong customer relationship and true value-added services provided to physicians

A team with operational and therapeutic expertise and strong track-record

A lean organization, with no overlap with Ipsen's existing structures

23

A well positioned product on the market

Apokyn

®

,

the

only

product

indicated

in

the

treatment

of

off

episodes

of

Parkinson's

disease

Ipsen will benefit from the acceleration of its growth perspectives

while

bearing

at

the

same

time

the

pre-launch

costs

of

Dysport

®

Gaining full control of  
OBI-1 s development  
Claire Giraut, Chief Financial Officer

25

Gaining full control over a promising compound  
Leveraging our know-how in hematology  
by gaining full rights to the product s  
development and commercialisation

1  
2  
4

Ipsen  
produced  
and  
commercialized  
the  
only  
plasma-derived  
porcine  
Factor  
VIII  
until  
2004,  
Hyate  
C

and optimise its development and time to market  
for a highly specialized hospital product, generating high revenue per patient  
An incremental investment to capture a significant revenue opportunity

3

in order to fulfill a high unmet medical need

Acquired  
hemophilia  
is  
an  
orphan  
disease  
(prevalence  
of  
1.5  
per  
million):  
6%  
to  
22%  
of  
patients  
die  
from  
bleeding  
The  
development  
of  
OBI-1  
will  
benefit  
from  
Ipsen's  
integrated  
approach  
and

specific  
knowledge  
base  
in  
hemophilia  
A  
with  
inhibitor  
and  
plasma-derived  
porcine  
Factor  
VIII  
Potential peak sales worldwide in excess of \$200 million

Transaction details

In 1998, Emory

University

licensed to Octagen its patents on OBI-1, who in turn granted a worldwide, exclusive sublicense to Ipsen.

Octagen was responsible for the pre-clinical and clinical development of OBI-1 and sublicensed certain rights to Ipsen in connection with the manufacturing, regulatory activities and commercialization of OBI-1.

Ipsen agreed to make milestone payments to Octagen and to pay royalties based on OBI-1 future net sales.

Ipsen  
purchased  
c.21.5%  
of  
Octagen's  
share  
capital.

Ipsen to acquire all Octagen's  
assets related to OBI-1

Upfront payment of \$10.5

million ( 6.8 million) to Octagen,

Potential additional payments contingent on entry of the product  
into P.III and on marketing approvals

Mid single digit royalty on net sales (including that to Emory)

Redemption of its stake in Octagen

26

A unique agent for the emergency care of acquired hemophilia  
Incidence of this autoimmune disease on the increase with the ageing population  
Silent disease often revealed under elective or emergency surgery  
Uncontrollable bleed due to antibodies against patient's factor VIII  
OBI-1 provides fast controllable dose-responsive formation of blood clots through the intrinsic pathway of coagulation  
Upon stabilization of hemostasis, patients are treated to full recovery (using Rituxan)  
OBI-1 will benefit from a strong support from the hematology community built by Ipsen



Ipsen produced and commercialized the only plasma-derived porcine Factor VIII until 2004

Ipsen will control all pre-clinical and clinical development activities

OBI-1 development will benefit from this integrated approach and Ipsen's specific knowledge in hemophilia A with inhibitor and plasma-derived porcine Factor VIII

Ipsen will now seek to confirm next steps towards registration, in liaison with regulatory agencies, with first feedback expected in 2008

27

Revised financial outlook  
Claire Giraut, Chief Financial Officer

Revised financial outlook

Ipsen confirms its standalone objectives for 2008,  
and will revise its full-year financial objectives once the closing dates of all  
transactions announced today are known

2008

Sales growth: 12.0 to 14.0%

(1)

compared to Ipsen's standalone objectives for 2008

2009

Operating margin: around 15%

(2)

(in % of total sales)

Creating a North American platform expected to generate sales in excess of \$300 million in

2012

(1)

and potentially close to \$1 billion by the end of the next decade

NOTE 1: At constant exchange rate

NOTE 2: Before taking into account transaction-related recordings or purchase accounting impacts

NOTE 3: Excluding any assumption on GLP-1 potential future royalty stream

Group operating margin expected to return to its 2007 level in 2011

(3)

29

A continued commitment to innovation, with a R&D expense of 19.0 to 21.0% of total sales

Conclusion

Jean-Luc Bélingard, Chairman & CEO

Delivering on our strategic objectives  
ENRICHING our R&D PIPELINE with new R&D projects  
DIVERSIFYING our geographic FOOTPRINT  
CREATING  
a  
global  
care  
solution

in  
endocrinology  
worldwide  
with the strength of A SINGLE GLOBAL VOICE in the market  
ENHANCING our GROWTH profile  
ENHANCING the contribution of our SPECIALIST CARE portfolio  
MINIMISING execution RISKS

31  
CONFIRMING OUR GLOBAL specialty care AMBITIONS  
CREATING

a  
MARKET  
VEHICLE  
for  
DYSPORT

®

Update to investors  
Ipsen will hold a  
Strategic and R&D day  
on Tuesday November 18, 2008  
in Paris (France)  
to provide further updates  
32



APPENDICES

33

Parkinson s disease  
medical considerations  
Parkinson s  
disease  
(PAD)  
is  
a  
progressive

neuro-degenerative  
disease  
affecting  
one s  
ability  
to  
control  
movement.

In  
PAD,  
cells  
that  
produce  
the  
neurotransmitter  
dopamine,  
primarily  
in  
the  
substantia  
nigra,  
die  
prematurely.

The  
resulting  
decrease  
in  
dopamine  
levels  
interferes  
with  
the  
ability  
to  
control  
movement  
and  
other  
motor  
functions.

At  
the  
time  
of  
diagnosis,  
most  
PAD  
patients  
have  
already

lost  
over  
80%  
of  
their  
dopamine  
producing  
cells.

Approximately one million people suffer from PAD in the US  
50,000 diagnosed annually

1% Americans age >60 have PAD

4-10% cases are young onset (diagnosed prior to age 40)

Number of PAD patients is expected to increase as the US population ages

34

Parkinson s disease  
Therapeutic options  
There  
is  
no  
known  
cure  
for

PAD,  
disease  
modification  
or  
neuroprotection  
remains  
the  
ultimate  
goal  
of  
treatment  
strategies  
and  
product  
development  
Current  
therapy  
is  
targeted  
entirely  
to  
symptom  
management,  
balancing  
efficacy  
with  
tolerability  
ON  
periods  
of  
relatively  
good  
mobility  
and  
well  
controlled  
motor  
function.  
OFF  
periods  
of  
poor  
or  
no  
mobility  
that  
are  
characterized  
by  
slow

movements  
and  
rigidity.

Dyskinesia  
periods  
of  
uncontrolled,  
seemingly  
random  
movements  
that  
occur  
during

ON  
episodes  
The  
goal  
of  
PAD  
therapy  
is  
to  
maximize  
the  
amount  
of  
time

a  
patient  
spends  
in  
the

ON  
state  
without  
troubling  
dyskinesias

The  
progressive  
nature  
of

PAD  
results  
in  
virtually  
all  
patients  
receiving  
multiple  
therapies

All existing therapies have side effects that can limit dosing and/or length of therapy. Treatments are usually broken into two groups; those used in early disease and those for advanced disease. Early disease treatments are predominately medical. Advanced disease treatments include both medical and surgical options.

35



36	
Tercica: key facts	
Product portfolio	
Summary Financials	
(18)	
(40)	
(83)	
Net Income	

(19)

(40)

(86)

EBIT

5

31

2

Total Revenues

Q1 08

2007

2006

(\$m)

Increlex

®

approved for marketing in the  
United States and the European Union;

Somatuline

®

Depot

®

approved for  
marketing in the United States and

Canada; and

Combination

of

Genentech's

recombinant human growth hormone

(rhGH) and recombinant human insulin-

like growth factor-1 (rhIGF-1)

Company description

Nasdaq

listed, California-based

biopharmaceutical company developing

and marketing endocrine products

Market capitalisation

of ~\$230 million

A strong market reach

Sales & marketing efforts target

approximately 500 pediatric

endocrinologists practicing in the US